Signpath Pharma, Inc.

Sighpath Pharma Inc.

Avanti Polar Lipids, Inc.

Annie Bouchard

Lawrence Helson

George M Shopp

Muhammed Majeed

James D McChesney

Daniel Emil Levy

Saravanan Kappusamy

John Kallikat Augustine

Walter Allen Shaw

Stephen W Burgess

Stephen Burgess

James Mcchesney

John Kallikat Angustine

Compositions and methods are provided for preventing one or more cardiac channelopathies or conditions resulting from irregularities or alterations in cardiac patterns, or both, in a human or animal subject comprising: one or more pharmacologically active agents that causes at least one of Ichannel inhibition or QT prolongation by inhibiting the activity of an ether-a-go-go-related gene (hERG); and one or more liposomes, wherein the liposomes are empty liposomes and administered prior to, concomitantly, or after administration of the pharmacologically active agent.

Liposomal mitigation of drug-induced inhibition of the cardiac Ichannel

The present invention includes a method of treating a drug-induced atrioventricular (AV) block comprising: providing a subject in need of therapy a drug that is contraindicated to treat a disease or condition in the subject, wherein the drug causes an AV block, with an amount of a lipid sufficient to reduce or eliminate the AV block caused by the drug.

Prevention of drug-induced atrio-ventricular block

The present invention includes compound having the following structural formula:

Cardiopathy-reducing phosphodiester lipids

The present invention includes compound having the following structural formula: 

The present invention includes compositions and methods for preventing one or more cardiac channelopathies or conditions resulting from irregularities or alterations in cardiac patterns caused by an active agent or a drug in a human or animal subject comprising: an amount of a lysophosphatidylglycerol adapted for oral administration effective to reduce or prevent one or more cardiac channelopathies or conditions resulting from irregularities or alterations in cardiac patterns caused by the active agent or drug.

Protective effect of DMPC, DMPG, DMPC/DMPG, lysoPG and lysoPC against drugs that cause channelopathies

Liposomal mitigation of drug-induced inhibition of the cardiac ikr channel

The present invention includes compositions and methods for preventing one or more cardiac channelopathies or conditions resulting from irregularities or alterations in cardiac patterns caused by an active agent or a drug in a human or animal subject comprising: an amount of a lysophosphatidyl compound adapted for oral administration effective to reduce or prevent one or more cardiac channelopathies or conditions resulting from irregularities or alterations in cardiac patterns caused by the active agent or drug. Such compositions may further comprise a monoglyceride, a free fatty acid or a combination of the foregoing, including, e.g., a eutectic mixture.

Protective effect of DMPC, DMPG, DMPC/DMPG, EGPG, LysoPG and LysoPC against drugs that cause channelopathies

The present invention includes compositions and methods for preventing one or more cardiac channelopathies or conditions resulting from irregularities or alterations in cardiac patterns caused by an active agent or a drug in a human or animal subject comprising: an amount of a phosphatidylglycerol adapted for oral administration effective to reduce or prevent one or more cardiac channelopathies or conditions resulting from irregularities or alterations in cardiac patterns caused by the active agent or drug, and one or more organoleptic, thixotropic, or both organoleptic and thixotropic agents.

Growing community of inventors

Stoke, Canada

Annie Bouchard